Nulibry

Chemical Namefosdenopterin
Dosage FormInjection (intravenous; 9.5 mg)
Drug ClassMetabolic agents
SystemNervous
CompanyOrigin Biosciences
Approval Year2021

Indication

  • Indicated to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A
Last updated on 3/14/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Nulibry (fosdenopterin) Prescribing Information.2021Alcami Carolinas Corporation, Charleston, SC